• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Zertifizierung, Einkauf und Qualitätssicherung

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration & DMF – Pharmaceuticals
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • CML (China Manufacture Licence) – Pressure vessels
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • About us
    • Partners
    • Company Profile
    • Testimonials
  • Locations
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Knowledge
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • Pharmaceuticals & DMF
      • CCC
      • Pressure Vessels
    • Whitepapers
    • FAQ – NMPA Registration – Medical Devices and IVDs
    • Newsletter Sign Up
    • Others
      • Publications
      • Online Shop
Contact
  • Home
  • News
  • News
  • NMPA Registration in China
  • Medical Device
  • China post-market surveillance regulatory research meeting – 2022 summary report

China post-market surveillance regulatory research meeting – 2022 summary report

China post-market surveillance
Thursday, 29 December 2022 / Published in Medical Device, News, NMPA Registration in China

China post-market surveillance regulatory research meeting – 2022 summary report

China post-market surveillance regulations for medical devices in 2022 were being reviewed in a meeting carried out by the National Medical Products Administration (NMPA) on December 8, 2022.

Work report on laws and regulations in different provinces and cities

During the meeting, the provincial medical products administration units provided a summary report on each respective regulatory research work carried out for supervision of medical device production, operation, network sales, sampling inspection, adverse event monitoring and case investigation in 2022:

  • The Medical Products Administration of Zhejiang Province took the lead in drafting documents such as “Opinions on Strengthening the Collaborative Supervision of Cross-Regional Commissioned Production of Medical Devices” to continuously enrich the production supervision system and promote the implementation of responsibilities of all parties.
  • The Medical Products Administration of Jilin Province took the lead in completing the research on third-party logistics of medical devices, and provided support for the release of the “Appendix of Medical Device Operation Quality Management Standards: Quality Management of Enterprises Specializing in Medical Device Transportation and Storage Services”.
  • The Medical Products Administration of Shandong Province conducts research on the investigation, evaluation and recall of products that do not meet the requirements of sampling inspection, improves the disposal procedures of technical means of supervision and sampling inspection, and promotes the improvement of work efficiency.
  • The Medical Products Administration of Peking enriched the basis of adverse event monitoring and evaluation from the aspects of regulations, technology and cases.
  • The Medical Products Administration of Guangdong Province investigated the implementation of laws and regulations of third-party platform enterprises and online sales enterprises of medical device online trading services, and put forward relevant suggestions on the difficulties, pain points and obstacles of grassroots supervision.
  • The Medical Products Administration of Hunan Province investigated the implementation of rules, norms and systems in the use process and put forward suggestions for revision and improvement.
  • The Medical Products Administration of Jiangsu Province compared the new models such as cross-regional commissioned production under the full implementation of the registrant system, and studied how to carry out supervision and law enforcement more effectively in practice.

Further information

Click here to read the full announcement of the meeting held to review the medical device post-market surveillance regulations in 2022.

If you would like to learn more about the China post-market surveillance requirements or how we can support you to comply with the requirements for selling medical devices in China, please contact us.

GET IN TOUCH

🌐 Send us your enquiry
📚 Request our whitepapers
📣 Sign up for our newsletter

What you can read next

NMPA report on the registration of medical devices in 2013, 2014, 2015
CSAR China cosmetics infringements
CSAR China cosmetics infringements lead to suspension of lavender essential oil production
Cisema Webinar: Report Launch – The Healthcare Market in China (2021 Update)

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Health Food
      • Medical Device
      • Pharmaceuticals & DMF
    • RoHS
    • Voluntary Product Certification
  • Publications
  • Seminars
  • Uncategorized
  • Webinars

Recent Posts

  • China cosmetics efficacy claims FAQ

    China cosmetics efficacy claims FAQ available to answer key questions

    China cosmetics efficacy claims FAQ is availabl...
  • China cosmetics GMP inspections

    China cosmetics GMP inspections points have been finalised

    China cosmetics GMP inspections points and judg...
  • China medical device quality safety responsibility

    China medical device quality and safety responsibility regulations come into force on March 1, 2023

    China medical device quality and safety respons...
  • China drug standards draft measures

    China drug standards draft measures have been published by the NMPA

    China drug standards draft measures have recent...
  • China special equipment safety supervision

    China special equipment safety supervision – draft provisions released

    China special equipment safety supervision regu...

Archive

Cisema

With twelve locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Newsletter Signup
  • Events
  • News & Knowledge
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2021 Cisema. All rights reserved.

TOP
Cookies on Cisema
Learn more about Cisema's Privacy Policy.